V-Wave’s Post

🔔 Join us TOMORROW for this critical discussion that delves deep into how to take disparities in outcomes, clinical trials and support into account to ensure every patient receives the attention they deserve. Register now: https://ow.ly/Scmj50RaQyX

We drive advancements in how this disease is cared for. One way we do this is through our our "International Expert Clinical Case series" (IECC). Launched in 2021, our IECC series helps drive discussion and collaboration amongst the #HHT medical community. Hosted by Cure HHT and held bi-monthly, each virtual meeting focuses on a different and specific topic area of HHT -- from brain to lung to spine to liver and more. Challenging cases are presented, and experts from around the world discuss and debate best practices and standards of care -- all in the name of driving better patient outcomes. Learn more about how we drive impact: https://lnkd.in/gDEyhNP9

Knowledge is Power! Patients with MDS can learn from Dr. Hetty Carraway in this recent Seattle Patient and Family Conference recording. Families of these patients can understand more, too, by watching here: https://lnkd.in/eSDTbcYA #MDS #bloodcancer

Congratulations Laura Esserman on your success with the ISPY Platform Trials (for advanced and aggressive breast cancer). Here are my notes from today's Press Conference National Press Club: Randomized clinical trials (#RCT) came from agriculture more than 60-years ago. Platform trials may allow for better targeting of therapies for patients. Three problems with RCT: (1) Expensive and long time to get RTC going. Protocols and agreements are put in place (this can take more than a year) then it’s locked down and investigators can no longer update or add any new science >> Platform trials use master protocols that allow for innovative science to be more easily incorporated (2) Mean results  Everyone’s disease is different; how they respond to therapy can also be different (heterogeneity of drug effects) >> Platform trials allow for flexibility in how the patient responds to the initial therapy; if the first therapy is unsuccessful, they can pivot to another therapy offered in the trial. (3) Current trials are innovation-centered NOT patient center and results must always be compared with the standard of care (this is true for new approach methodologies (#NAMs) like #insilico) >>Platform trials allow investigators to track how the patients are getting better because ISPY is “#SMART”: Sequential, Multiple, Assigned, Randomized Trial Patients start in one block and can move to other blocks if the treatment isn’t working. They have different drugs from different companies in one trial.  Pathologic Complete Response (#PCR) – this is the tracked short-term metric Some challenges with adopting platform trials: >> still need to demonstrate causal inference - that the drug caused the change >> Platform trials require a lot of new infrastructure and training and so it’s challenging to embrace a new paradigm Still to do: - better predictive endpoints - while collecting the prelim data for ISPY trial only took 2 years; the #FDA approval can take several more years. Best wishes on this journey Dr. Esserman.

Webinar on November 12: Join us for The Clinical PE Story: PEERLESS RCT Comparing FlowTriever to CDT, an in-depth discussion on the results of the PEERLESS randomized controlled trial. This symposium will explore the RCT outcomes and offer valuable clinical insights into the future of PE intervention and patient care. https://bit.ly/3Uowje9

Join the webinar Nov 12th!

Join us on November 12 as we dive into the results of the #PEERLESS RCT!

Knowledge is Power! Patients with MDS can learn from Dr. Hetty Carraway in this recent Seattle Patient and Family Conference recording. Families of these patients can understand more, too, by watching here: https://lnkd.in/eSDTbcYA #MDS #bloodcancer

Would you recognize the history, clinical signs, and presentation of a severe DKA? Join Dr. Johnson to learn how to stabilize the patient and formulate a diagnostic and treatment plan. https://lnkd.in/g6c9nRTX

Join us Tuesday, 11/12 for The Clinical PE Story: PEERLESS RCT Comparing FlowTriever to CDT, an in-depth discussion on the results of the PEERLESS randomized controlled trial. This webinar will explore the RCT outcomes and offer valuable clinical insights into the future of PE intervention and patient care. https://bit.ly/3Uowje9